← back to search

Teele Kuusk

University of Cambridge · GB
Area of research
Pulmonary and Respiratory Medicine · Surgery
Research interest
Research interests include Renal cell carcinoma treatment, Bladder and Urothelial Cancer Treatments, Renal and related cancers, and Multiple and Secondary Primary Cancers.
h-index
23
citations
4,785
works
71
NIH funding
primary concept
email

Recent publications

European Association of Urology Guidelines on Renal Cell Carcinoma: The 2025 Update
European Urology 2025cited by 186position: middledoi
Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitors and Subsequent Therapy for Renal Cell Carcinoma
European Urology 2025cited by 23position: middledoi
Hospital Volume as a Determinant of Outcomes After Partial Nephrectomy: A Systematic Review by the European Association of Urology Renal Cell Carcinoma Guidelines Panel
European Urology Oncology 2025cited by 6position: middledoi
Sentinel lymph node staging in urological cancer surgery: advances in imaging, intra‐operative detection and translational research
British Journal of Urology 2025cited by 2position: middledoi
Cambridge kidney One-Stop Mass Investigation Clinic (CkOSMIC): A Nonrandomised Feasibility Study
European Urology Oncology 2025cited by 1position: middledoi
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update
European Urology 2022cited by 1,471position: middledoi
The 2022 Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitor Therapy for Renal Cell Carcinoma
European Urology 2022cited by 50position: middledoi
European Association of Urology Guidelines Panel on Renal Cell Carcinoma Update on the New World Health Organization Classification of Kidney Tumours 2022: The Urologist’s Point of View
European Urology 2022cited by 35position: middledoi
A Renewal of the TNM Staging System for Patients with Renal Cancer To Comply with Current Decision-making: Proposal from the European Association of Urology Guidelines Panel
European Urology 2022cited by 32position: middledoi
Reply to Yaxiong Tang, Xu Hu, Kan Wu, Yanxiang Shao, and Xiang Li’s Letter to the Editor re: Umberto Capitanio, Jens Bedke, Laurence Albiges, et al. A Renewal of the TNM Staging System for Patients with Renal Cancer To Comply with Current Decision-making: Proposal from the European Association of Urology Guidelines Panel. Eur Urol. 2022;83:3–5
European Urology 2022cited by 10position: middledoi
The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor–based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care
European Urology 2021cited by 151position: middledoi
2021 Updated European Association of Urology Guidelines on the Use of Adjuvant Pembrolizumab for Renal Cell Carcinoma
European Urology 2021cited by 45position: middledoi
Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma
European Urology 2020cited by 134position: middledoi
Limitations of Available Studies Prevent Reliable Comparison Between Tumour Ablation and Partial Nephrectomy for Patients with Localised Renal Masses: A Systematic Review from the European Association of Urology Renal Cell Cancer Guideline Panel
European Urology Oncology 2020cited by 78position: middledoi
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update
European Urology 2019cited by 1,515position: middledoi
Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma
European Urology 2019cited by 209position: middledoi
Management of Sporadic Renal Angiomyolipomas: A Systematic Review of Available Evidence to Guide Recommendations from the European Association of Urology Renal Cell Carcinoma Guidelines Panel
European Urology Oncology 2019cited by 116position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Axel Bex · Dutch Cancer Society16 papers (2019–2025)Alessandro Volpe · Università degli Studi del Piemonte Orientale “Amedeo Avogadro”15 papers (2019–2025)Lorenzo Marconi · St Thomas' Hospital15 papers (2019–2025)Milan Hora · Institute of Medical Sciences15 papers (2019–2025)Laurence Albigès · Institut Gustave Roussy14 papers (2019–2025)Saeed Dabestani · Lund University14 papers (2019–2025)Börje Ljungberg · Umeå University13 papers (2019–2025)Yasmin Abu‐Ghanem · University of Dundee13 papers (2019–2025) · 13 papers (2019–2025) · 12 papers (2019–2022)Rana Tahbaz · Humboldt-Universität zu Berlin12 papers (2019–2022)Tobias Klatte · Helios Hospital Bad Saarow11 papers (2020–2025)Umberto Capitanio · University of Bologna11 papers (2020–2025)Jens Bedke · Medical University of Vienna11 papers (2020–2025)Thomas Powles · Twitter (United States)9 papers (2019–2022)Thomas Lam · Sun Yat-sen University Cancer Center8 papers (2019–2022)Rachel H. Giles · Utrecht University7 papers (2019–2022)Thomas Powles · St Bartholomew's Hospital5 papers (2019–2025)Rachel Giles · Utrecht University5 papers (2021–2022)Riccardo Campi · Virginia Commonwealth University4 papers (2022–2025)